↓ Skip to main content

MiRNAs as biomarkers and therapeutic targets in cancer☆

Overview of attention for article published in Current Opinion in Pharmacology, October 2010
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
158 Dimensions

Readers on

mendeley
167 Mendeley
citeulike
3 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
MiRNAs as biomarkers and therapeutic targets in cancer☆
Published in
Current Opinion in Pharmacology, October 2010
DOI 10.1016/j.coph.2010.05.010
Pubmed ID
Authors

Helen M Heneghan, Nicola Miller, Michael J Kerin

Abstract

The knowledge that miRNA expression is frequently dysregulated in cancer has uncovered an entirely new repertoire of molecular factors upstream of gene expression, with exciting potential as novel biomarkers and therapeutic targets in cancer. Exploiting the unique characteristics of these molecules including their stability, tissue specificity, ease of detection and manipulation, will bring clinicians ever closer to achieving the goal of individualized cancer treatment. We present a comprehensive and timely review of the role of miRNAs in cancer. Herein we address briefly miRNA biogenesis, the putative role of miRNAs as oncogenes or tumor suppressors, and their potential as sensitive and specific tumor markers with particular emphasis on the commonest cancers; breast, prostate, lung and colorectal. We also discuss circulating tumor-associated miRNAs which are emerging as clinically useful tools for early detection, prognostication and management of various cancers. Finally we explore their potential therapeutic applications in the field of cancer and highlight some of the potential challenges that need to be overcome in order to bring miRNAs from bench to bedside. Given the evidence to date, we envisage a pivotal role for miRNAs in the future individualized management of cancer patients.

Mendeley readers

The data shown below were compiled from readership statistics for 167 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Belgium 2 1%
Brazil 2 1%
Portugal 1 <1%
Malaysia 1 <1%
United Kingdom 1 <1%
France 1 <1%
China 1 <1%
Russia 1 <1%
Spain 1 <1%
Other 2 1%
Unknown 154 92%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 43 26%
Researcher 32 19%
Student > Master 24 14%
Student > Bachelor 23 14%
Student > Postgraduate 10 6%
Other 24 14%
Unknown 11 7%
Readers by discipline Count As %
Agricultural and Biological Sciences 68 41%
Medicine and Dentistry 40 24%
Biochemistry, Genetics and Molecular Biology 26 16%
Engineering 3 2%
Pharmacology, Toxicology and Pharmaceutical Science 3 2%
Other 9 5%
Unknown 18 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2014.
All research outputs
#10,902,996
of 12,303,777 outputs
Outputs from Current Opinion in Pharmacology
#889
of 994 outputs
Outputs of similar age
#218,188
of 270,168 outputs
Outputs of similar age from Current Opinion in Pharmacology
#17
of 19 outputs
Altmetric has tracked 12,303,777 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 994 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,168 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.